Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Thurs Jan 9th, the US Stock Markets will be closed in observance of a national day of mourning for former President Jimmy Carter. Read the press release here. Regular trading hours will resume tomorrow.

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Fibrogen Inc CS 350 Bay Street Suite 100 #6009 SAN FRANCISCO CA 94158 USA

www.fibrogen.com Employees: 486 P: 415-978-1200 F: 415-978-1902

Description:

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 65,581
Enterprise Value, $K 45,301
Shares Outstanding, K 100,770
Annual Sales, $ 147,750 K
Annual Net Income, $ -284,230 K
Last Quarter Sales, $ 46,330 K
Last Quarter Net Income, $ -17,080 K
EBIT, $ -112,950 K
EBITDA, $ -108,080 K
60-Month Beta 0.75
% of Insider Shareholders 1.98%
% of Institutional Shareholders 72.71%
Float, K 98,775
% Float 98.02%
Short Volume Ratio 0.18

Growth:

1-Year Return -17.08%
3-Year Return -95.46%
5-Year Return -98.53%
5-Year Revenue Growth -30.62%
5-Year Earnings Growth -146.60%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.17 on 11/12/24
Next Earnings Date 02/24/25
Earnings Per Share ttm -1.23
EPS Growth vs. Prev Qtr -6.25%
EPS Growth vs. Prev Year 67.31%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

FGEN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -36.17%
Profit Margin % -192.37%
Debt/Equity -0.33
Price/Sales 0.36
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -2.22
Interest Coverage -17.47
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar